EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pro-Calcifying Role of Enzymatically Modified LDL (eLDL) in Aortic Valve Sclerosis via Induction of IL-6 and IL-33

Annemarie Witz, Denise Effertz, Nora Goebel, Matthias Schwab, Ulrich F W Franke, Michael Torzewski

Biomolecules · 2023

DOI: 10.3390/biom13071091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Annemarie Witz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Calcinosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Robert Bosch Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the contributors to atherogenesis is enzymatically modified LDL (eLDL). eLDL was detected in all stages of aortic valve sclerosis and was demonstrated to trigger the activation of p38 mitogen-activated protein kinase (p38 MAPK), which has been identified as a pro-inflammatory protein in atherosclerosis. In this study, we investigated the influence of eLDL on IL-6 and IL-33 induction, and also the impact of eLDL on calcification in aortic valve stenosis (AS). eLDL upregulated phosphate-induced calcification in valvular interstitial cells (VICs)/myofibroblasts isolated from diseased aortic valves, as demonstrated by alizarin red staining. Functional studies demonstrated activation of p38 MAPK as well as an altered gene expression of osteogenic genes known to be involved in vascular calcification. In parallel with the activation of p38 MAPK, eLDL also induced upregulation of the cytokines IL-6 and IL-33. The results suggest a pro-calcifying role of eLDL in AS via induction of IL-6 and IL-33.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisCalcinosisHumansAortic ValveInterleukin-6SclerosisInterleukin-33Cells, Culturedp38 Mitogen-Activated Protein Kinases

Stichwörter der Autor:innen

IL-33IL-6VICs/myofibroblastsaortic valve stenosiscalcificationenzymatically modified LDL (eLDL)p38 MAPK

Substanzen

Interleukin-6Interleukin-33p38 Mitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
  • Department of Cardiovascular Surgery, Robert-Bosch-Hospital, 70376 Stuttgart, Germany.
  • Department of Clinical Pharmacology, University of Tuebingen, 72076 Tuebingen, Germany.
  • Department of Biochemistry and Pharmacy, University of Tuebingen, 72076 Tuebingen, Germany.
  • Department of Laboratory Medicine and Hospital Hygiene, Robert-Bosch-Hospital, 70376 Stuttgart, Germany.

Förderung

  • Robert Bosch Stiftung

Zitieren

APA

Witz, A., Effertz, D., Goebel, N., Schwab, M., Franke, U. F. W., & Torzewski, M. (2023). Pro-Calcifying Role of Enzymatically Modified LDL (eLDL) in Aortic Valve Sclerosis via Induction of IL-6 and IL-33. Biomolecules. https://doi.org/10.3390/biom13071091

Vancouver

Witz A, Effertz D, Goebel N, Schwab M, Franke UFW, Torzewski M. Pro-Calcifying Role of Enzymatically Modified LDL (eLDL) in Aortic Valve Sclerosis via Induction of IL-6 and IL-33. Biomolecules. 2023. doi:10.3390/biom13071091

BibTeX
@article{Witz2023,
  author = {Witz, Annemarie and Effertz, Denise and Goebel, Nora and Schwab, Matthias and Franke, Ulrich F W and Torzewski, Michael},
  title = {Pro-Calcifying Role of Enzymatically Modified LDL (eLDL) in Aortic Valve Sclerosis via Induction of IL-6 and IL-33},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13071091}
}
Kostenlos starten →